布地奈德福莫特罗粉、噻托溴铵联合无创通气应用于COPD伴Ⅱ型呼吸衰竭中的效果探讨
2018-09-03宋飞
宋飞
[摘要] 目的 探討布地奈德福莫特罗粉、噻托溴铵联合无创通气应用于慢性阻塞性肺疾病(COPD)伴Ⅱ型呼吸衰竭中的效果。 方法 方便选择2014年8月—2016年8月该院收治的COPD伴Ⅱ型呼吸衰竭患者98例,以随机数字表法将其分为对照组(行常规对症治疗措施)与研究组(在对照组的基础上应用布地奈德福莫特罗粉、噻托溴铵联合无创通气治疗),每组49例。观察对比两组临床治疗效果、治疗前后肺功能与血气指标的变化。 结果 研究组治疗的总有效率为95.92%,高于对照组79.59%(χ2=6.078,P<0.05)。治疗后研究组FEV1(2.82±0.52)L、FEV1占预计值百分比(75.60±4.20)%、FEV1/FVC(78.85±4.65)均高于对照组(1.98±0.22)L、(64.56±4.52)%、(66.58±4.58)(t=3.856,4.526, 4.985,P<0.05),PaO2(77.85±6.65)mmHg高于对照组(70.50±5.68)mmHg(t=4.252,P<0.05),PaCO2(60.50±6.58)mmHg低于对照组(68.88±5.60)mmHg(t=4.356,P<0.05)。结论 布地奈德福莫特罗粉、噻托溴铵联合无创通气应用于COPD伴Ⅱ型呼吸衰竭患者中效果满意,可以有效改善其肺功能与血气指标,值得临床推广。
[关键词] 布地奈德福莫特罗粉;噻托溴铵;无创通气;COPD;Ⅱ型呼吸衰竭
[中图分类号] R5 [文献标识码] A [文章编号] 1674-0742(2018)04(c)-0001-03
Study on Application Effect of Budesonide Formoterol Powder, Tiotropium Bromide Combined with Noninvasive Ventilation in COPD with Type II Respiration Failure
SONG Fei
Department of Respiration Medicine, Linzi District Maternal and Infant Healthcare Hospital, Linzi, Shandong Province, 255400 China
[Abstract] Objective To study the effect of budesonide formoterol powder, tiotropium bromide combined with noninvasive ventilation in COPD with type II respiration failure. Methods 98 cases of patients with COPD with type II respiration failure admitted and treated in our hospital from August 2014 to August 2016 were conveniently selected and randomly divided into two groups, with 49 cases in each, the control group used the routine systematical treatment measures, and the research group used the budesonide formoterol powder, tiotropium bromide combined with noninvasive ventilation on the basis of the control group, and the clinical treatment effect, and changes of lung function and blood gas indicators were compared between the two groups. Results The total treatment effective rate in the research group was higher than that in the control group(95.92% vs 79.59%)(χ2=6.078, P<0.05) , after treatment, the FEV1, percentage of FEV1 in the predicative values and FEV1/FVC in the research group were higher than those in the control group[(2.82±0.52)L, (75.60±4.20) %, (78.85±4.65) vs (1.98±0.22)L, (64.56±4.52)%, (66.58±4.58) (t=3.856, 4.526, 4.985, P<0.05), and the PaO2, was higher than those in the control group [(77.85±6.65)mmHg, (70.50±5.68)mmHg(t=4.252, P<0.05) ], and the PaCO2 was lower than that in the control group [(60.50±6.58)mmHg vs (68.88±5.60)mmHg(t=4.356, P<0.05) ]. Conclusion The application effect of budesonide formoterol powder, tiotropium bromide combined with noninvasive ventilation in COPD with type II respiration failure is satisfactory, which can effectively improve the lung functions and blood gas index, and it is worth clinical promotion.
[Key words] Budesonide formoterol powder; Tiotropium bromide; Noninvasive ventilation; COPD; Type II respiration failure
慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)是一组以持续气流受阻为主要特征的疾病,可进一步发展为肺心病与呼吸衰竭。其中Ⅱ型呼吸衰竭属于COPD的常见并发症,具有起病急、病情危重等特点,给患者的健康与生命安全带来了巨大的危害[1]。目前,COPD并Ⅱ型呼吸衰竭主要采用激素、支气管扩张剂、抗感染、吸氧与纠正酸碱平衡等方案治疗,但临床收效却参差不齐[2]。无创正压通气作为呼吸内科最为常用的治疗措施,具有操作简便、创伤小等特点,可以有效维持肺的通气与氧合作用,继而缓解患者的临床症状。2014年8月—2016年8月该院对49例COPD伴Ⅱ型呼吸衰竭患者应用了布地奈德福莫特罗粉、噻托溴铵联合无创通气治疗,临床取得了满意的效果,现报道如下。
1 资料与方法
1.1 一般资料
方便选择该院收治的COPD伴Ⅱ型呼吸衰竭患者98例。纳入标准:根据《实用内科学》第14版[3]中的诊断标准确诊。……
